PCC
TRIB

Park Circle Company’s Trinity Biotech TRIB Stock Holding History

Park Circle Company’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-800
Closed -$24K – 91
2017
Q1 		$24K Hold
800
– – 0.02% 79
2016
Q4 		$28K Buy
800
+200
+33% +$6.89K 0.02% 86
2016
Q3 		$40K Hold
600
– – 0.03% 80
2016
Q2 		$34K Hold
600
– – 0.02% 76
2016
Q1 		$35K Buy
600
+360
+150% +$19.1K 0.03% 73
2015
Q4 		$14K Buy
+240
New +$14.2K 0.01% 89

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

Park Circle Company's TRIB Position: Q2 2017 in Review

Park Circle Company sold out of Trinity Biotech (TRIB) in Q2 2017, closing a stake of 800 shares — an estimated $24K sold.

Park Circle Company first reported a position in TRIB in Q4 2015 and held it in 6 quarters. The position peaked at $40K in Q3 2016. 56 funds tracked by Wall St. Rank hold TRIB as of Q2 2017.

  • Park Circle Company reported no remaining Trinity Biotech position as of Q2 2017 after selling out during the quarter.
  • Park Circle Company sold 800 Trinity Biotech shares in Q2 2017, an estimated $24K.
  • Park Circle Company first reported a position in Trinity Biotech in Q4 2015 and held it in 6 quarters.
  • Park Circle Company's Trinity Biotech position peaked at $40K in Q3 2016.
  • 56 funds tracked by Wall St. Rank held Trinity Biotech as of Q2 2017.

Based on Park Circle Company's 13F filing for Q2 2017, filed 8 Aug 2017.